$30.94
0.87% day before yesterday
NYSE, Jan 02, 10:08 pm CET
ISIN
US8816242098
Symbol
TEVA

Teva Pharmaceutical Industries Limited Sponsored ADR Stock price

$30.95
+4.07 15.14% 1M
+13.90 81.52% 6M
-0.26 0.83% YTD
+9.65 45.31% 1Y
+21.83 239.36% 3Y
+20.61 199.32% 5Y
-34.35 52.60% 10Y
-12.06 28.04% 20Y
NYSE, Closing price Fri, Jan 02 2026
-0.26 0.83%
ISIN
US8816242098
Symbol
TEVA
Industry

New AI Insights on Teva Pharmaceutical Industries Limited Sponsored ADR Insights AI Insights on Teva Pharmaceutical Industries Limited Sponsored ADR

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
$35.8b
Enterprise Value
$50.4b
Net debt
$14.6b
Cash
$2.2b
Shares outstanding
1.1b
Valuation (TTM | estimate)
P/E
50.7 | 11.5
P/S
2.1 | 2.1
EV/Sales
3.0 | 2.9
EV/FCF
87.2
P/B
4.9
Dividends
DPS
$0.00
Yield 1Y | 5Y
0.0% | 0.0%
Growth 1Y | 5Y
- | -
Payout 1Y | 3Y
0.0% | 0.0%
Increased
0 Years
Financials (TTM | estimate)
Revenue
$16.8b | $17.3b
EBITDA
$4.8b | $5.0b
EBIT
$3.8b | $4.4b
Net Income
$712.0m | $3.1b
Free Cash Flow
$578.0m
Growth (TTM | estimate)
Revenue
0.0% | 4.6%
EBITDA
-3.6% | 8.1%
EBIT
-3.4% | 23.6%
Net Income
171.7% | 289.2%
Free Cash Flow
-57.8%
Margin (TTM | estimate)
Gross
51.3%
EBITDA
28.8% | 29.0%
EBIT
22.8%
Net
4.2% | 17.9%
Free Cash Flow
3.5%
Financial Health
Equity Ratio
13.7%
Return on Equity
-30.5%
ROCE
13.5%
ROIC
9.4%
Debt/Equity
2.3
More
EPS
$0.6
FCF per Share
$0.5
Short interest
3.9%
Employees
-
Rev per Employee
-
Show more

Is Teva Pharmaceutical Industries Limited Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,082 stocks worldwide.

Teva Pharmaceutical Industries Limited Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Teva Pharmaceutical Industries Limited Sponsored ADR forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Teva Pharmaceutical Industries Limited Sponsored ADR forecast:

Buy
86%
Hold
14%

Financial data from Teva Pharmaceutical Industries Limited Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
16,776 16,776
0% 0%
100%
- Direct Costs 8,165 8,165
1% 1%
49%
8,611 8,611
1% 1%
51%
- Selling and Administrative Expenses 3,803 3,803
4% 4%
23%
- Research and Development Expense 994 994
2% 2%
6%
4,829 4,829
4% 4%
29%
- Depreciation and Amortization 1,011 1,011
4% 4%
6%
EBIT (Operating Income) EBIT 3,818 3,818
3% 3%
23%
Net Profit 712 712
172% 172%
4%

In millions USD.

Don't miss a Thing! We will send you all news about Teva Pharmaceutical Industries Limited Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Teva Pharmaceutical Industries Limited Sponsored ADR Stock News

Positive
The Motley Fool
7 days ago
Prague-based Pale Fire Capital SE added 639,162 shares of Teva in the third quarter. The overall position value increased by $16.53 million from the previous period.
Neutral
GlobeNewsWire
10 days ago
TEL AVIV, Israel, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that S&P Global Ratings ("S&P") has upgraded Teva's long-term issuer credit rating to ‘BB+' from ‘BB', with a stable outlook, and that Moody's Ratings Agency ("Moody's") affirmed Teva's B1a rating and revised Teva's outlook to positive from stable. These upgrades mark an...
Negative
The Motley Fool
10 days ago
Quarterly-filed Form 13Fs allow investors to track which stocks Wall Street's savviest money managers are buying and selling. Billionaire Stanley Druckenmiller dumped his fund's stakes in AI darlings Nvidia and Palantir -- and profit-taking may not explain the entire story.
More Teva Pharmaceutical Industries Limited Sponsored ADR News

Company Profile

Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The company was founded in 1901 and is headquartered in Petah Tikva, Israel.

Head office Israel
CEO Richard Francis
Founded 1901
Website www.tevapharm.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today